Uploaded January 2026 | Updated November 2026, 2 days ago
Dr. Kellie Smith is an Associate Professor of Oncology in the Bloomberg-Kimmel Institute for Cancer Immunotherapy at the Johns Hopkins School of Medicine. In this interview, Dr. Smith shares how she came to study science and specialize in T-cell immunology and immunotherapy. She also discusses how she developed an original assay for detecting anti-tumor immune responses in specific types of lung cancer, called MANASCORE. She also shares some details about the goal of comprehensively understanding immunotherapy-resistant immune cells. Dr. Smith reveals the basic thought process that led her to a focus on integrating multi-omics technologies to study tumor-reactive T cells in the setting of various cancer types, with a specific focus on lung cancer; what brought her to Johns Hopkins, and how remaining at the institution throughout her career been an asset to her research.
In a field that is highly technical and requires sustained, years-long dedication that some people could find draining or otherwise unrewarding — the big Hollywood moments are presumably rare. Dr. Smith describes how she paces herself, determines benchmarks, and frames big-picture questions that structure her work.
Finally, scientists have long worked at the center of the tension between advancing (empirical) knowledge, and the realities of socio-political and cultural pressures. Dr. Smith discusses how scientists should grapple with the current tension.
Episode Resources:
• Profile Page, Johns Hopkins Medicine (profiles.hopkinsmedicine.org/provider/kellie-n-smith/2777132)
• Google Scholar Page (scholar.google.com/citations?user=6j1rcL4AAAAJ&hl=en)
• Keynote Presentation: Immunogenomic Characterization of Tumor-Reactive TIL in Lung Cancers w/ Live Q&A (labroots.com/webinar/keynote-presentation-immunogenomic-characterization-tumor-reactive-til-lung-cancers-w-live-q-a)
• Keynote Presentation: Characterizing the phenotype, function, and spatial interactions of tumor-reactive TIL (labroots.com/webinar/keynote-presentation-characterizing-phenotype-function-spatial-interactions-tumor-reactive-til)
Connect & explore more: Visit The Life of Her Mind (labroots.com/podcast-series/life-of-her-mind) to listen, share, and access links and resources. Check out Labroots scholarship opportunities here (labroots.com/scholarships) . Submit a scientific poster to be featured in our event(s) here (labroots.com/posters) .
Dr. Kellie Smith is an Associate Professor of Oncology in the Bloomberg-Kimmel Institute for Cancer Immunotherapy at the Johns Hopkins School of Medicine. In this interview, Dr. Smith shares how she came to study science and specialize in T-cell immunology and immunotherapy. She also discusses how she developed an original assay for detecting anti-tumor immune responses in specific types of lung cancer, called MANASCORE. She also shares some details about the goal of comprehensively understanding immunotherapy-resistant immune cells. Dr. Smith reveals the basic thought process that led her to a focus on integrating multi-omics technologies to study tumor-reactive T cells in the setting of various cancer types, with a specific focus on lung cancer; what brought her to Johns Hopkins, and how remaining at the institution throughout her career been an asset to her research.
In a field that is highly technical and requires sustained, years-long dedication that some people could find draining or otherwise unrewarding — the big Hollywood moments are presumably rare. Dr. Smith describes how she paces herself, determines benchmarks, and frames big-picture questions that structure her work.
Finally, scientists have long worked at the center of the tension between advancing (empirical) knowledge, and the realities of socio-political and cultural pressures. Dr. Smith discusses how scientists should grapple with the current tension.
Episode Resources:
• Profile Page, Johns Hopkins Medicine (profiles.hopkinsmedicine.org/provider/kellie-n-smith/2777132)
• Google Scholar Page (scholar.google.com/citations?user=6j1rcL4AAAAJ&hl=en)
• Keynote Presentation: Immunogenomic Characterization of Tumor-Reactive TIL in Lung Cancers w/ Live Q&A (labroots.com/webinar/keynote-presentation-immunogenomic-characterization-tumor-reactive-til-lung-cancers-w-live-q-a)
• Keynote Presentation: Characterizing the phenotype, function, and spatial interactions of tumor-reactive TIL (labroots.com/webinar/keynote-presentation-characterizing-phenotype-function-spatial-interactions-tumor-reactive-til)
Connect & explore more: Visit The Life of Her Mind (labroots.com/podcast-series/life-of-her-mind) to listen, share, and access links and resources. Check out Labroots scholarship opportunities here (labroots.com/scholarships) . Submit a scientific poster to be featured in our event(s) here (labroots.com/posters) .


![Evolving Respiratory Viral Testing in the Post-Pandemic Era: Clinical and Lab Perspectives
In the post–COVID-19 pandemic era, the role of respiratory viral testing continues to evolve. Explore the clinical value of testing and what positive results mean for patient management and treatment decisions, all while connecting clinical and laboratory insights to demonstrate how optimized respiratory testing can support better decision-making and efficiency in today’s healthcare environment.
Disclaimer: Waters Corporation has acquired BD [Biosciences/Diagnostic Solutions]. BD remains the legal manufacturer until all required regulatory transfers are complete. Learn more: www.waters.com/bdtransaction (https://www.waters.com/bdtransaction) Evolving Respiratory Viral Testing in the Post-Pandemic Era: Clinical and Lab Perspectives](https://i.ytimg.com/vi/QIWA5SrLomA/mqdefault.jpg)







